《大行報告》里昂降海吉亞醫療(06078.HK)目標價至49元 拋售創造買入機會
里昂發表報告指,海吉亞醫療(06078.HK)於前日(11日)收市後召開業務更新電話會議,將今年全年有機收入增長指引從20%以上,下調至16%以上,將經調整淨利潤增長指引從25%以上,下調至介乎17%至20%。管理層預計明年的有機收入增長率介乎15%至25%,經調整淨利潤按年增長率為25%以上。
該行下調對海吉亞醫療每股盈利預測,以反映新的指引。同時認為該股昨日(12日)被拋售,股價挫逾20%提供買入機會。明年基本面能見度應較高,下行風險有限。重申「買入」評級,目標價由63元下調至49元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.